Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 11;11(1):37.
doi: 10.3390/jpm11010037.

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review

Johanna Raymond  1   2 , Laurent Imbert  2   3 , Thibault Cousin  1 , Thomas Duflot  3 , Rémi Varin  1 , Julien Wils  2   3 , Fabien Lamoureux  2   3
Affiliations
Review

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review

Johanna Raymond et al. J Pers Med. .

Abstract

Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed.

Keywords: adverse drug reactions; clinical implementation; direct oral anticoagulants; pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Picard N., Boyer J.C., Etienne-Grimaldi M.C., Barin-Le Guellec C., Thomas F., Loriot M.A., French National Network of Pharmacogenetics (RNPGx) Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx) Therapie. 2017;72:185–192. doi: 10.1016/j.therap.2016.09.014. - DOI - PubMed
    1. Bertoletti L., Ollier E., Duvillard C., Delavenne X., Beyens M.N., De Magalhaes E., Bellet F., Basset T., Mismetti P., Laporte S. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol. Res. 2017;118:33–42. doi: 10.1016/j.phrs.2016.06.023. - DOI - PubMed
    1. Pradaxa: Summary of Product Characteristics. [(accessed on 27 August 2020)]; Available online: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-....
    1. Xarelto: Summary of Product Characteristics. [(accessed on 27 August 2020)]; Available online: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-....
    1. Eliquis: Summary of Product Characteristics. [(accessed on 27 August 2020)]; Available online: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-....

LinkOut - more resources